Project Grant 2052049
Award Date
5/1/21
Completion Date
6/30/22
Dollars Obligated
$256K
Federal Agency
National Science Foundation
Awardee
Biosapien Inc. (D98WXLCWRQC9)
Federal Grant Program
47.084
Assistance Type
Project Grant
Place of Performance
New York, NY 10003, USA
Similar Awards
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Phase I Small Business Innovation Research (SBIR) grant, awarded to Tissueform, Inc., a for-profit woman-owned small business in Boulder, Colorado, aims to develop a library of human-based bioinks for 3D bioprinting applications. The $274,822 award, with a performance period from September 2024 to August 2025, will focus on creating granulated bioinks for tissues such as cartilage, bone, skin, liver,...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $304,906 to Seabird Lifesciences LLC supports the development of an innovative bioprinting approach for creating vascular grafts that closely mimic the properties of natural blood vessels. The project aims to overcome limitations of current synthetic and biological grafts by utilizing a specialized bioprinting process that integrates a double-network hydrogel made from a Dacron...
Biochip Labs Inc. received a $256,000 National Science Foundation Project Grant under the Engineering program (CFDA 47.041) for the period of June 1, 2021 through May 31, 2022. The grant funding supports the company's work to develop standardized and reproducible culture and activation methods for endothelial cells in microfluidic devices for drug screening applications. The NSF Engineering program seeks to improve quality of life and economic strength through engineering research and...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $305,000 to Novaurum Biosciences Incorporated supports the development of a novel mammalian cell-based nano-biological coating for implantable medical devices. The key objectives are to: (1) characterize nanoparticles produced by different cells on orthopedic implant materials, (2) determine the antibacterial, anti-inflammatory, and cell proliferation properties of the coated...
Biomesense Inc. received a $255,658 National Science Foundation SBIR Phase I Project Grant to develop a novel biosensor to accelerate investigations of COVID-19 and the gut microbiome. Funded under the NSF Engineering program (CFDA 47.041), this six-month award beginning January 15, 2021 supports the company's work to design a portable, low-cost biosensor device capable of rapidly detecting SARS-CoV-2 and analyzing gut microbiome composition directly from patient samples. The NSF Directorate for...
This $256,000 Project Grant from the National Science Foundation's Technology, Innovation, and Partnerships program will support the development of additive manufacturing techniques for soft tissue repair. Asante Bio LLC will receive funding to design and engineer a novel 3D microfiber printer capable of assembling synthetic biopolymer filaments into fibrous, flexible implants that promote soft tissue healing. Through this six-month award ending November 2022, Asante Bio will optimize...
Nostopharma LLC was awarded a $256,000 Small Business Technology Transfer Phase I Project Grant from the National Science Foundation to develop a sustained-release, biodegradable nanoparticle drug delivery system for treatment of soft tissue trauma complications. Funded under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084), the 12-month project beginning March 1, 2022 aims to demonstrate in vitro and in vivo feasibility of modulating the ectopic bone microenvironment...
This $252,906 National Science Foundation project grant supports the development of scalable manufacturing methods for peptide amphiphile molecules by Amphix Bio Inc. The goal is to advance a safer and more affordable alternative to recombinant proteins currently used in spinal fusion surgeries. Over 500,000 such surgeries are performed annually in the U.S. to treat back and neck pain. While peptide amphiphiles show promise for reducing biological dose needs and offering consistent outcomes,...
Simmbion LLC was awarded a $255,136 Project Grant from the National Science Foundation's Small Business Technology Transfer program to develop a system for manufacturing drug therapies inside the human body. Over the one-year period from April 2022 to March 2023, the company will genetically engineer symbiotic blood organisms to express and secrete two therapeutic proteins - β-glucocerebrosidase to treat Gaucher's disease and insulin for diabetes treatment. In vitro and in vivo testing will...
This Project Grant award from the National Science Foundation (CFDA 47.084 - NSF Technology, Innovation, and Partnerships program) provides $275,000 to Ubiquitx Inc., a New York-based small business, to develop a programmable, modular therapeutic platform for the direct modification of proteins of interest (POIs) using artificial intelligence, protein engineering, and mRNA therapeutics. The goal is to expand the applications of the company's Chimeric Ligands for Induced Proximity (CLIPS)...